期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

他莫昔芬辅助治疗:5年或10年?

Adjuvant tamoxifen therapy: 5 years or 10 years?
暂未订购
导出
摘要 他莫昔芬是乳腺癌内分泌治疗的里程碑式药物,占据了30余年的"金标准"地位。目前他莫昔芬的标准治疗时间是5年,但是乳腺癌的复发风险长期存在,我们是否应该更长时间地应用他莫昔芬来降低乳腺癌复发风险。结合目前最新研究进展,我们就这一问题进行了深入阐述。 Tamoxifen is a monumental drug in endocrine therapy of breast cancer. It has been the ＂golden standard＂ tbr more than 30 years. At present, the standard treatment time of adjuvant tamoxifen is 5 years. Considering the long-term recurrence risk of breast cancer, is it better to continue tamoxifen beyond 5 years？ Based on the latest research progress, we discussed this problem in depth.
作者 薛妍 刘文超
机构地区 第四军医大学西京医院肿瘤科
出处 《医学争鸣》 CAS 北大核心 2014年第1期44-46,共3页 Negative
基金 第四军医大学西京医院学科助推计划(XJZT10Y24)
关键词 他莫昔芬 辅助治疗 乳腺癌 tamoxifen adjuvant therapy breast cancer
分类号 R730.1 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials[J]. Lancet, 2011, 378(9793): 771-784.
  • 2Saphner T, Tormey DC, Gray R. Annual hazard rates of recmTence for breast cancer after primary therapy[J]. J Clin Oncol, 1996, 14(10):2738-2746.
  • 3Fisher B, Dignmn J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial[J]. J Natl Cancer |nst, 2001, 93(9):684-690.
  • 4Stewart H J, Forrest AP, Everington D, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Breast Group[J]. Br J Cancer, 1996, 74(2):297-299.
  • 5Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Ontology Group[J]. J Natl Cancer Inst, 1996, 88(24):1828-1833.
  • 6Delozier T, Spielmann M, Mace-Lesecal J, et al. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with longterm treatment. Federation Nationale des Centres de Lutte Contre le Cancer Breast Group[J]. J Clin Oncol, 2000, 18(20):3507-3512.
  • 7Cmrent Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer[J]. J Natl Cancer Inst, 1996, 88(24):1834-1839.
  • 8Fisher B, Brown A, Wolmark N, et al. Prolonging tamoxition therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial[J]. Ann Intern Med, 1987, 106(5):649-654.
  • 9Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer[J]. J Natl Cancer Inst, 1996, 88(2 1): 1543-1549.
  • 10Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381 (9869):805-816.
医学争鸣
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部